Drug Type Small molecule drug |
Synonyms 4-methylumbelliferone, Htmecromone, Hymecreomone + [14] |
Target |
Action modulators |
Mechanism Hyaluronic acid modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date (13 May 2025), |
RegulationOrphan Drug (United States) |
Molecular FormulaC10H8O3 |
InChIKeyHSHNITRMYYLLCV-UHFFFAOYSA-N |
CAS Registry90-33-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00170 | Hymecromone |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Biliary Tract Diseases | - | - | 13 May 2025 |
Cholestasis | - | - | - |
Spasm | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Idiopathic Pulmonary Fibrosis | Phase 2 | United States | 05 May 2025 | |
Cholangitis, Sclerosing | Phase 2 | United States | 10 May 2023 | |
Cholangitis, Sclerosing | Phase 2 | United States | 10 May 2023 | |
Hypertension, Pulmonary | Phase 2 | United States | - | |
Respiratory Diseases | Phase 1 | United States | 01 Dec 2020 | |
Myocardial Ischemia | Preclinical | Iran | 06 Jan 2024 | |
Reperfusion Injury | Preclinical | Iran | 06 Jan 2024 | |
Hepatocellular Carcinoma | Preclinical | Italy | 20 Apr 2023 | |
Brain Diseases | Preclinical | France | 16 Nov 2022 | |
Multiple Sclerosis | Discovery | United States | - |
Phase 2 | Hypertension, Pulmonary hyaluronan (HA) | 16 | nowaubhmbs(sytfwvkeqs) = widymonbwi kpzfzigrcz (nsonehcqbx, -1.5 to 2.7) View more | Positive | 15 Aug 2025 | ||
Phase 2 | 17 | (Experimental Treatment Oral Hymecromone (H01)) | ihovajkejk(rhsjgbnoec) = croivjwwdi tgpvupkouw (ahnnkezmgr, 2.65) View more | - | 26 Nov 2024 | ||
Placebo (Placebo) | ihovajkejk(rhsjgbnoec) = jnfdcegkqv tgpvupkouw (ahnnkezmgr, 4.16) View more |